Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6196321 | 0.81 | GRM2 (0.37) | GRM2GRM3CNR1CNR2OPRM1 | |
| SCHEMBL6194742 | 0.81 | GRM2 (0.37) | GRM2GRM3CNR1CNR2OPRM1 | |
| SCHEMBL6494472 | 0.77 | SPHK1 (0.39) | GRM2GRM3CNR1CNR2NAAA | |
| SCHEMBL6196335 | 0.76 | CTSS (0.34) | GRM2GRM3CNR1CNR2OPRM1 | |
| SCHEMBL27788552 | 0.65 | OPRM1 (0.42) | GRM2GRM3OPRM1OPRD1OPRK1 | |
| SCHEMBL14338696 | 0.65 | SPHK1 (0.42) | SIGMAR1 | |
| SCHEMBL6924329 | 0.65 | SPHK1 (0.42) | SIGMAR1 | |
| SCHEMBL6505406 | 0.63 | — | — | |
| SCHEMBL17103824 | 0.61 | PPARA (0.34) | — | |
| SCHEMBL1760152 | 0.61 | BRD4 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872740-B2 | Use of 2-amino-4-heteroarylethyl-thiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2005-03-29 | — | — | US | disclosed |
| US-20030225140-A1 | 4-(heteroarylethyl)-4,5-dihydro-1,3-thiazol-2-ylamine or salt, useful for treating an illness, which involves an abnormal production of nitric oxide (NO) by induction of an inducible NO-synthase | AVENTIS PHARMA S.A. (FR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225140-A1 | 4-(heteroarylethyl)-4,5-dihydro-1,3-thiazol-2-ylamine or salt, useful for treating an illness, which involves an abnormal production of nitric oxide (NO) by induction of an inducible NO-synthase | PTGS1, PTGIS, NOS1 | GRM2 990/4885GRM3 1548/4885CNR1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.